338 related articles for article (PubMed ID: 32153557)
1. Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis.
Jiang T; Huang Y; Liu H; Xu Q; Gong Y; Chen Y; Hu X; Han Z; Gao M
Front Immunol; 2020; 11():37. PubMed ID: 32153557
[No Abstract] [Full Text] [Related]
2. MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway.
Yin Y; Li F; Shi J; Li S; Cai J; Jiang Y
Cell Physiol Biochem; 2016; 40(3-4):486-498. PubMed ID: 27889748
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1.
Liu Y; Gao Y; Yang J; Shi C; Wang Y; Xu Y
Int J Oncol; 2018 Sep; 53(3):1332-1342. PubMed ID: 29956737
[TBL] [Abstract][Full Text] [Related]
4. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.
Liu T; Hou Y; Dai TJ; Yan CZ
Chin Med J (Engl); 2017 Sep; 130(17):2101-2106. PubMed ID: 28836555
[TBL] [Abstract][Full Text] [Related]
6. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis.
Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C
J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-409-3p regulates macrophage migration in polymyositis through targeting CXCR4.
Ye Q; Chen Z
Autoimmunity; 2021 Sep; 54(6):353-361. PubMed ID: 34142881
[TBL] [Abstract][Full Text] [Related]
8. Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.
Son K; Tomita Y; Shimizu T; Nishinarita S; Sawada S; Horie T
Intern Med; 2000 Feb; 39(2):128-35. PubMed ID: 10732829
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis.
Jiang Q; Li Y; Xia L; Shen H; Lu J
J Interferon Cytokine Res; 2019 Nov; 39(11):720-725. PubMed ID: 31274382
[TBL] [Abstract][Full Text] [Related]
10. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production.
Sugiura T; Kawaguchi Y; Harigai M; Takagi K; Ohta S; Fukasawa C; Hara M; Kamatani N
J Immunol; 2000 Jun; 164(12):6593-600. PubMed ID: 10843719
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis.
Silva MG; Oba-Shinjo SM; Marie SKN; Shinjo SK
Clin Exp Rheumatol; 2019; 37(4):656-662. PubMed ID: 30620283
[TBL] [Abstract][Full Text] [Related]
12. MIRSNP rs2910164 of miR-146a is associated with the muscle involvement in polymyositis/dermatomyositis.
Okada Y; Jinnin M; Makino T; Kajihara I; Makino K; Honda N; Nakayama W; Inoue K; Fukushima S; Ihn H
Int J Dermatol; 2014 Mar; 53(3):300-4. PubMed ID: 24716199
[TBL] [Abstract][Full Text] [Related]
13. Integrated comparison of the miRNAome and mRNAome in muscles of dermatomyositis and polymyositis reveals common and specific miRNA-mRNAs.
Gao S; Zhang H; Zuo X; Xiao Y; Liu D; Zhu H; Luo H
Epigenomics; 2019 Jan; 11(1):23-33. PubMed ID: 30523707
[TBL] [Abstract][Full Text] [Related]
14. Potential role of autophagy in T‑cell survival in polymyositis and dermatomyositis.
Shu X; Chen F; Peng Q; Lu X; Tian X; Wang Y; Wang G
Mol Med Rep; 2017 Aug; 16(2):1180-1188. PubMed ID: 28586060
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.
Gabay C; Gay-Croisier F; Roux-Lombard P; Meyer O; Maineti C; Guerne PA; Vischer T; Dayer JM
Arthritis Rheum; 1994 Dec; 37(12):1744-51. PubMed ID: 7986220
[TBL] [Abstract][Full Text] [Related]
16. T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.
Houtman M; Ekholm L; Hesselberg E; Chemin K; Malmström V; Reed AM; Lundberg IE; Padyukov L
Arthritis Res Ther; 2018 Aug; 20(1):188. PubMed ID: 30157932
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases.
Shen H; Xia L; Lu J
Cytokine; 2012 Nov; 60(2):334-7. PubMed ID: 22863719
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
19. Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.
Zhou H; Wang Y; Bi K; Qi H; Song S; Zhou M; Chen L; Wang G; Duan T
Clin Rheumatol; 2019 May; 38(5):1425-1431. PubMed ID: 30645753
[TBL] [Abstract][Full Text] [Related]
20. Estrogen Downregulates miR-21 Expression and Induces Inflammatory Infiltration of Macrophages in Polymyositis: Role of CXCL10.
Yan W; Chen C; Chen H
Mol Neurobiol; 2017 Apr; 54(3):1631-1641. PubMed ID: 26873848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
